Table 3.
Low-density lipoprotein cholesterol (LDL-C) concentrations and measurement characteristics at baseline and post-evolocumab therapy initiation
| Outcome | Value |
|---|---|
| Baseline LDL-C concentration, mmol/L (N = 119)∗ | |
| Mean ± SD | 3.7 ± 1.7 |
| Median (IQR) | 3.5 (2.5–4.6) |
| Average number of LDL-C tests post-evolocumab initiation (N = 131) | |
| Mean ± SD | 2 ± 1 |
| Frequency of LDL-C measurements (N = 131) | |
| 0 | 11 (8.4) |
| 1 | 31 (23.7) |
| 2 | 48 (36.6) |
| > 2 | 41 (31.3) |
| Time from evolocumab therapy initiation to LDL-C measurement, d, median (IQR; N = 120)† | |
| First measurement | 55 (33-106) |
| Last measurement | 247 (162-315) |
| Overall LDL-C concentration post-evolocumab therapy (N = 120)† | |
| Mean ± SD, mmol/L | 1.6 ± 1.0 |
| Median (IQR) | 1.20 (0.75–2.14) |
| Incidence of LDL-C < 1.8 mmol/L (N = 120)† | 93 (77.5) |
| In FH patients (N = 66) | 47 (71.2) |
| In non-FH patients (N = 54) | 46 (85.2) |
| Incidence of LDL-C reduction ≥ 50% (N = 109) | 78 (71.6) |
Values are n (%), unless otherwise indicated.
FH, familial hypercholesterolemia; HDL, high-density lipoprotein; IQR, interquartile range; SD, standard deviation; TC, total cholesterol; TG, triglyceride.
The last LDL-C concentration measured within 6 months prior to initiation of evolocumab therapy in 119 patients with available data was regarded as the baseline LDL-C concentration. Twelve patients did not have a baseline LDL-C concentration reported.
Eleven patients did not have an LDL-C measurement post-evolocumab therapy initiation, of which 3 patients had other lipid measures taken (total cholesterol, HDL, non-HDL, and triglyceride; data not reported), and 8 patients had no lipid tests.